Budget Impact Analysis of Comprehensive Genomic Profiling in Advanced Non–Small Cell Lung Cancer in Taiwan

Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non–Small Cell Lung Cancer

“…CGP can identify genomic alterations often missed with less comprehensive testing, 14,15 and CGP-tested patients are more likely to be treated with beneficial targeted therapies. [14][15][16][17][18][19][20] In addition, treatment guided by CGP has been shown to decrease health care costs 13,[21][22][23] and increase clinical trial enrollment. The Center for Medicare and Medicaid Services covers CGP testing starting in 2018 as do a growing number of commercial payers in the United States.…”

“…[95% CI, 0.18 to 1.23]), squamous/other histology (OR, 0.31 [95% CI, 0.13 to 0.62]), and current smoking (OR, 0.15 [95% CI, 0.07 to 0.31]) or former smoking (OR, 0.37 [95% CI, 0.21 to 0.64]).When survival was assessed separately for those who received systemic therapy and those who did not, CGP-tested patients had better survival than small panel-tested patients in both treated (median rwOS, 22[18][19][20][21][22][23][24][25] v 15[14][15][16] months) and untreated patients (median rwOS, 10 [6-15] v 4[4][5] months; Fig1). Among the subset of treated patients with an OncoKB level 1 or 2 actionable biomarker detected, patients who received matched therapy had improved survival compared with patients who received unmatched therapies only in both the CGP-tested (median rwOS, 34[21- 49] matched therapy v 14[10][11][12][13][14][15][16][17][18] unmatched therapy) and small panel-tested groups (median rwOS, 27[21-43] matched therapy v 10 [8-14] unmatched therapy; Fig 2).…”